Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA), following treatment with any erythropoietin should not receive Epoetin alfa or any other erythropoietin (see Precautions).
Hypersensitivity to the active substance or to any of the excipients.
All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with Epoetin alfa.
The use of Epoetin alfa in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
Surgery patients who for any reason cannot receive adequate antithrombotic prophylaxis.